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Abstract: The key role of p53 as a tumor suppressor became clear when it was realized that this gene
is mutated in 50% of human sporadic cancers, and germline mutations expose carriers to cancer risk
throughout their lifespan. Mutations in this gene not only abolish the tumor suppressive functions of
p53, but also equip the protein with new pro-oncogenic functions. Here, we review the mechanisms
by which these new functions gained by p53 mutants promote tumorigenesis.
Keywords: TP53; mutant TP53; gain of function; oncogenic
1. Introduction
TP53 (Tumor Protein P53) is among the most extensively studied human genes [1,2]. The main
explanation for this interest is its key role in preventing tumor development. Indeed, the transcription
factor p53 is the principal mediator of cellular responses to several stressors, such as DNA damage,
oncogene activation, nutrient deprivation, and hypoxia [3,4]. In unstressed cells, p53 activity is
negatively regulated by MDM2 (Mouse Double Minute 2), which binds to p53 and promotes its
proteasomal degradation [5–8]. Interestingly, MDM2 itself is a p53 target gene [9–12]. Thus, p53 and
MDM2 establish an autoregulatory negative feedback loop, to maintain low cellular p53 levels in the
absence of stress. In response to a stress stimulus, both p53 and MDM2 undergo post-translational
modifications that block their interaction. As a result, MDM2-mediated inhibition is alleviated, leading
to p53 accumulation and activation [13]. The activation of p53 results in three major outcomes: growth
arrest, DNA repair, and apoptosis. Growth arrest causes a temporary arrest of cell cycle progression,
enabling the cell to correct damaged DNA, and prevent the replication of damaged DNA and the
transfer of the genetic aberrations to daughter cells. In addition to inducing cell cycle arrest, p53 also
promotes DNA repair [14–17]. Once DNA repair is complete, the cell cycle resumes. In contrast,
if the cell has severe DNA damage that is unable to be repaired, p53 eliminates the cell by inducing
programmed cell death [18]. Thus, p53 acts as a guardian of the genome by preventing the accumulation
of oncogenic mutations that could lead to tumor development [19].
The effects of p53 are mainly mediated by its transcriptional activity [20]. In particular, p53-induced
cell cycle arrest involves the transcriptional activation of CDKN1A/P21 (Cyclin Dependent Kinase Inhibitor
1A) [21–24]. During apoptosis, p53 increases the expression of a large number of genes, including
BBC3/PUMA (Bcl-2-Binding Component 3), PMAIP1/NOXA (PMA-Induced Protein 1), BAD (BCL2
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Associated Agonist Of Cell Death), BAX (BCL2 Associated X), BAK (BCL2 Antagonist), TP53AIP1 (Tumor
Protein P53 Regulated Apoptosis Inducing Protein 1), and FAS (Cell Surface Death Receptor) [25,26].
p53 also functions in DNA repair by transcriptionally regulating the expression of genes involved
in several DNA damage repair (DDR) pathways. In vivo shRNA screens targeting p53-regulated genes
demonstrate that DNA repair is a crucial mechanism in p53 suppression of tumor development [27].
p53 has been shown to exert this role at different levels, for example in Nucleotide Excision Repair
(NER), p53 induces DDB2 (Damage Specific DNA Binding Protein 2) and XPC (XPC Complex
Subunit), two components of the NER machinery [28]. p53 can also regulate the transcription of
Base Excision Repair (BER) genes such as OGG1 (8-Oxoguanine DNA Glycosylase) [29] and MUTYH
(MutY DNA Glycosylase) [30], which encode for an 8-oxoguanine glycosylase and an adenine DNA
glycosylase, respectively. p53 influences BER also though its ability to regulate the expression of
3-methyladenine (3-MeAde) DNA glycosylase, the first enzyme in the BER pathway [31], and APE1,
an apurinic/apyrimidinic (AP) endodeoxyribonuclease [32]. p53 also synergizes to the transcription
factor c-jun to regulate the transcription of the MSH2 (MutS Homolog 2) gene, encoding a component
of the DNA mismatch repair system (MMR) [33].
p53 also acts in DNA Double-Strand Break Repair (DNA-DSB). Nonhomologous End Joining
(NHEJ) and Homologous Recombination (HR) are the two pathways involved in DNA-DSB repair.
Although several studies suggest a connection between p53 and NHEJ [34,35], the role of p53 in this
process is still unclear. On the contrary, p53 has been shown to regulate HR by inducing the expression
of RAD51 (BRCA1/BRCA2-Containing Complex) [36]. In addition to these transcription-dependent
functions, p53 has been shown to have transcriptional independent functions in promoting tumor
suppression. For example, in the cytosol, p53 can directly bind and activate BAX. Upon activation,
BAX forms homo-oligomers that are inserted in the outer mitochondrial membrane (OMM), inducing
membrane permeabilization, cytochrome c release, and caspase-3 activation [37]. In the regulation of
the NER pathway, p53 has been shown to interact with the helicases XPB (Xeroderma Pigmentosum,
Complementation Group B) and XPD (Xeroderma Pigmentosum Complementary Group D), modulating
their activities [38,39]. Furthermore, p53 stimulates BER by interacting and stabilizing DNA pol β,
the main DNA polymerase involved in BER [40]. In addition, p53 modulates HR via direct interactions
with RAD51 and RAD54L (DNA Repair And Recombination Protein RAD54-Like) proteins [41].
The regions of p53 that are responsible for recognizing specific p53-binding elements in the
promoters of its target genes, and subsequent transcriptional activation, are well defined. The p53 protein
comprises a transactivation and a proline-rich domain (residues 1 to 43 and 61 to 94, respectively) located
at the N-terminus, a central DNA-binding domain (DBD) (residues 110 to 286), and a tetramerization
domain (TD) and regulatory region (residues 326 to 355 and 363 to 393, respectively), located at the
C-terminus. Among these domains, the TD allows the oligomerization of the protein, and the formation
of a tetrameric complex that represents the active conformation of p53 [42].
Although researchers initially postulated that p53 tumor suppressor activity was mainly
mediated through induction of cell cycle arrest and apoptosis, additional mechanisms have more
recently emerged [43]. Indeed, p53 also controls additional cellular processes that are potentially
important for suppressing tumor formation, such as the metabolism, autophagy, ferroptotic cell death,
and stemness [44–46].
2. p53 Mutations: One Gene Different Proteins
Given the fundamental role of p53 in restricting tumor formation, its inactivation is commonly
identified in human cancers [47]. Somatic mutations in p53 occur in over half of all human cancers,
while germline p53 mutations that abolish its function are observed in a hereditary form of cancer,
known as Li-Fraumeni syndrome [48]. Further supporting the role of p53 in preventing tumor
development, Trp53 knockout mice show a high predisposition to tumor formation [49].
TP53 gene has an unusual mutational pattern. Indeed, the gene is not frequently deleted but
is mainly subject to mutations, the majority of which are missense mutations located in the DNA
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binding domain [50] (Figure 1). Within this region, the most frequent mutations, known as hot
spots, are divided into two categories: conformational mutations (e.g., R175H) that lead to structural
changes in the binding domain, and contact mutations (e.g., R273H), that alter the ability of the protein
to bind DNA [51]. In both cases, these mutations alter the interaction of p53 with its consensus
DNA-binding sequence, impairing the activation of p53 target genes involved in suppressing tumor
growth. The frequency of somatic and germline hot spot p53 mutations in human cancer is reported
in Table 1. Very high levels of p53 mutant proteins accumulate in tumors because of their inability
to induce MDM2 expression [52]. However, p53 mutants have not only lost the tumor suppressor
function of wild type p53 associated with its transcriptional activity [53,54], but also exert a dominant
negative effect on the co-expressed wild type protein. Indeed, mutant p53 heterodimerizes with wild
type p53 to form complexes that impair its function [55–57]. p53 mutations are usually followed by the
deletion of the remaining wild type TP53 allele. This phenomenon, known as loss of heterozygosity
(LOH), suggests that despite the dominant negative effect exerted by p53 mutants, the complete loss
of wild type p53 provides cancer cells with a selective advantage [58]. Indeed, according to a recent
in vivo study, p53 LOH is required for mutant p53 stabilization, and the execution of additional
oncogenic functions. Indeed, mutant p53 proteins can also acquire novel pro-oncogenic properties,
an effect known as gain of function (GOF). In particular, mouse tumors that undergo to p53 loss of
heterozygosity at a high frequency exhibit stabilization of the mutant p53 protein, and an accelerated
tumor onset compared with p53+/− tumors. In contrast, in mouse tumors in which wild type p53 LOH
rarely occurs, the mutant p53 protein is not stabilized, and GOF activity is not observed [59].
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Figure 1. Analysis of TP53 genetic alterations. using cBioPortal data. (A). Frequency and type of TP53 
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Table 1. Frequency of six hot spot p53 mutations in several human cancers. The frequenty of both
somatic and germline p53 mutation is shown.
TUMOR TYPES
SOMATIC MUTATIONS FREQUENCY (%)
R175H R273H R248Q R248W G245S R273C
BILIARY TRACT 10.96 6.85 2.74 4.11 2.74
BLADDER 2.51 1.39 3.50 1.65 1.19 0.99
BONES 4.20 3.36 4.20 3.77 1.26 5.88
BRAIN 5.80 4.34 4.07 1.26 2.01 10.63
BREAST 4.52 3.30 3.72 3.09 1.39 1.22
CERVIX UTERI 4.27 2.56 5.13 2.85 1.71 5.13
COLON 8.56 5.68 4.98 1.71 4.02 4.45
COLORECTUM, NOS 10.91 5.68 5.74 4.54 3.86 2.39
CORPUS UTERI 2.76 3.23 3.69 0.92 2.30
ESOPHAGUS 5.07 2.45 2.61 3.09 1.39 1.39
GALLBLADDER 4.55 0.91 2.73
GUM 4.94 1.23 1.23 2.47 1.23 3.70
HEAD & NECK, NOS 2.56 1.50 2.41 1.95 0.75 1.05
HEMATOP. SYSTEM 4.71 2.68 8.89 1.61 1.71 1.71
HYPOPHARYNX 2.73 2.19 2.19 1.64 1.64 0.55
KIDNEY 3.40 1.36 3.40 2.72 1.36 1.36
LARYNX 1.37 2.06 1.83 1.60 0.23 1.37
LIVER 1.09 0.50 1.17 0.58 0.83 2.09
LUNG 1.21 1.77 1.21 1.54 0.33 0.88
LYMPH NODES 3.28 2.49 6.29 2.36 1.18 3.01
MOUTH (floor) 3.19 3.19 3.19
MOUTH (other) 3.64 0.87 3.20 1.16 1.31 1.75
NASAL CAVITY 1.05 2.11 0.53 1.58 1.05 0.53
NASOPHARYNX 4.84 24.19 3.23 1.61
OTHER FEMALE GEN. ORG. 16.00 4.00 4.00 4.00 4.00 4.00
OTHER RESPIR. SYST. 9.09 13.64 4.55 4.55
OVARY 4.64 4.08 2.34 2.52 1.43 2.30
PANCREAS 3.67 6.52 2.24 2.65 1.02 3.67
PENIS 14.29 28.57 7.14
PERITONEUM 2.17 4.35 2.17
PROSTATE 2.41 2.14 1.88 1.34 1.07 4.83
RECTOSIGM. JUNCT. 12.50 2.50 5.00 5.00 7.50
RECTUM 10.27 4.92 4.78 4.78 4.20
SINUSES 4.57 1.83 2.74 2.28 0.46 0.91
SKIN 0.57 0.57 1.81 4.37 1.05 0.57
SOFT TISSUES 1.69 2.66 1.94 2.18 2.42 0.97
STOMACH 6.84 3.17 3.58 3.17 3.17 2.76
TONGUE (other) 1.44 1.91 2.87 1.44 1.44 1.44
URINARY TRACT, NOS 20.00 0.58 1.16 0.58
UTERUS 5.48 2.74 4.11 6.85
VULVA 2.78 2.78 6.48 0.93 4.63 3.70
TUMOR TYPES
GERMLINE MUTATIONS FREQUENCY (%)
R175H R273H R248Q R248W G245S R273C
ADRENAL GLAND 6.96 3.09 4.0 7.21 1.3 1.64
BONES 8.7 14.43 11.0 6.31 3.9 3.28
BRAIN 14.78 8.25 11.0 24.32 9.84
BREAST 29.57 24.74 29.0 29.73 27.87
HEMATOP. SYSTEM 4.35 4.12 2.0 6.49 6.56
LUNG 0.87 4.12 3.0 2.7 5.19 6.56
SKIN 2.61 2.06 1.0 2.7 6.49 8.2
SOFT TISSUES 12.17 18.56 16.0 11.69 6.56
STOMACH 3.48 4.12 6.31 1.3 1.64
THYROID 0.87 1.03 2.0 3.6 3.28
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GOF in p53 is supported by evidence that mice expressing p53 R172H or R270H mutants
(equivalent to human R175H and R273H) develop a greater number of metastatic tumors than p53−/−
mice [60,61], and by the observation that patients with Li-Fraumeni syndrome carrying p53 missense
mutations are characterized by earlier tumor development, than patients with a p53 deletion [62].
Interestingly, different p53 mutant proteins are associated with different GOF effects. Indeed, distinct
cancer phenotypes were observed in knock-in mice harboring different p53 mutants. In particular,
p53R270H/+ mice had an increased incidence of carcinomas and B cell lymphomas compared to p53+/−.
In contrast to the frequent carcinomas in p53R270H/+ mice, p53R172H/+ mice developed mainly
osteosarcomas [61]. In addition, human p53 knock-in (hupki) mice harboring the hot spot mutation
R248Q, display an accelerated tumor onset and shorter survival, compared to p53-null mice. However,
homozygous G245S hupki mice had similar overall survival and tumor spectrums to their p53-null
counterparts, further supporting that different p53 mutants have variation in their GOF activities [63].
Consistently, Li-Fraumeni syndrome patients with different TP53 missense mutations showed different
tumor spectra. Specifically, the median age at diagnosis is 19.5 years for patients with mutations
at the R248Q codon, compared to 30 years for patients with a nonsense p53 mutation. However,
in Li-Fraumeni patients with R248Q mutation, the disease occurs on average at 19.5 years, in patients
with G245S TP53 mutations, the disease is diagnosed at a median age of 30.5 years [64].
Depending on the tumor type, p53 inactivation (deletions and/or mutations) can occur at different
steps of the malignant progression. In many solid tumors (colorectal cancer, pancreatic cancer, and breast
cancer for example), p53 mutations are among the later steps of the tumorigenesis, in other contexts,
these genetic events can occur at early stages (e.g., in esophageal carcinoma) [65–67]. Definitive studies
on the genetic evolution of cancers are only recently emerging. In pancreatic ductal adenocarcinoma
(PDAC) genetic evolution has been quite well defined. PDAC arises from precursor lesions (PanINs)
that progressively evolve toward the highly invasive and metastatic PDACs in which p53 is mutated
in 75% of cases. Concurrently, with SMAD4 (SMAD Family Member 4 inactivation), inactivating
mutations of TP53 occur only during the late phase of pancreatic carcinogenesis, following early
(activating mutations in KRAS Proto-Oncogene) and intermediate (inactivating mutations of Cyclin
Dependent Kinase Inhibitor 2A) genetic events [68]. The acquisition of p53 mutations during the
advanced stage of the disease might confer cancer cells high genomic instability, a metastatic phenotype,
and progression toward very aggressive PDACs.
To date, mutant p53 has been shown to promote oncogenic cellular changes by interacting
with other transcription factors (enhancing or impairing their transcriptional activity) or with
chromatin-modifying complexes, leading to alterations in the cellular transcriptional profile. It has
been suggested that missense mutations at different sites may impose specific conformational changes
that can influence the affinity of each p53 mutant protein for different binding partners. Thus, several
p53 mutants may have the ability to interact with different proteins resulting in the transactivation of
different set of target genes, and variations in cellular phenotypes [69]. Through these mechanisms,
p53 mutants have been shown to affect multiple aspects of cellular behavior and phenotypes, such as
metabolism, invasion, migration, and proliferation.
3. Mutant p53 and Cancer Therapy Resistance
The major aim of cancer therapy is to inhibit cell proliferation and promote cell death. Interestingly
p53 mutant expression has been associated with chemoresistance in breast cancer [70], ovarian
cancer [71], lung cancer [72], and gastric and colorectal cancers [73]. It is not only the loss of the
key pro-apoptotic function of wild type (wt) p53 to confers chemotherapy resistance, but also GOF
effects exerted by mutant p53 proteins to contribute to drug resistance. For example, p53 mutants
stimulate the expression of ABCB1 (ATP Binding Cassette Subfamily B Member 1), an ATP-binding
cassette (ABC) transporter, mediating the efflux of drugs from cells in a ATP-dependent manner,
conferring multi-drug resistance (MDR) [74]. Interestingly wt p53 exerts the opposite effect on ABCB1
expression compared to p53 mutants [75]. Interestingly p53 mutants block Ataxia Telangiectasia
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Mutated (ATM)-dependent activation of the DNA damage response (DDR) through the disruption
of the MRE11-RAD50-NSB complex. On the other hand, mutant p53 stimulates the activity of the
enzyme poly (ADP ribose) polymerase 1 (PARP1), allowing tumor cells to survive in the presence of
high levels of DNA damage [76,77]. In addition to the induction of chemoresistance, both in vitro [78]
and in vivo [79,80] studies have shown that p53 mutants are able to induce resistance to radiotherapy.
Moreover, in several human cancers, p53 mutants are associated with reduced radiosensitivity and
worse prognosis [73,81].
4. Effect of Mutant p53 GOF on p53 Family Members: Tumor Invasion and Metastasis
As discussed above, some solid tumors, such as PDAC, accumulate mutations in p53 in the later
stages of the tumor progression and this correlates with the acquisition of an invasive/metastatic
phenotype. Several possible mechanisms have been described to explain p53 mutant’s ability to drive
metastasis, such as involving the p53 homologs, p73 and p63 [82,83]. Given their high structural
similarity, p63 and p73 bind and activate many p53 target genes to regulate cell cycle arrest and
apoptosis, in response to cellular stress. Notably, p63 and p73 homo and heterodimerize with each
other, but do not interact with wild type p53. On the contrary, the conformational mutant p53R175H has
been shown to aggregate to the family members p63 and p73, through an interaction that involves its
DNA binding domain (DBD) and the C-terminal transactivation inhibitory (TI) domain of both p63 and
p73 α-isoforms. Supporting this hypothesis, the TAp63α that in normal conditions acquires a closed
conformation in which the TI domain is inaccessible, does not interact with p53R175H [84]. Through
this co-aggregation mechanism, mutant p53 proteins may exert a dominant negative effect on p63 and
p73, inhibiting their functions [85–87]. In particular, the formation of mutant p53/p63 or mutant p53/p73
complexes has been shown to promote invasion through several mechanism. The inhibition of p63
function mediated by the interaction with mutant p53 (both the R175H and R273H mutants) represses
SHARP-1 (Basic Helix-Loop-Helix Family Member E41) and Cyclin G2 expression, promoting cell
migration and invasion. Phospho-SMAD2 (SMAD family member 2), a component of the transforming
growth factor beta (TGFβ) signaling pathway that serves as a scaffold for p53-p63 complex assembly,
plays a key role in this process (Figure 2A) [88,89]. In addition, the mutant p53-dependent suppression
of p63 activity increases the Rab coupling protein (RCP)-driven recycling of α5β1 integrin and EGFR
(epidermal growth factor receptor) to the cell surface, leading to the activation of Rho and PKB/Akt
signaling that promote cell migration and invasion [90]. In pancreatic cancer, mutant R172H p53 has
been shown to interact with p73, blocking the interaction of p73 with NF-Y (nuclear transcription factor
Y), which in turn induces the expression of PDGFRβ (platelet-derived growth factor receptor beta),
which is important for maintaining a metastatic phenotype (Figure 2A) [91].
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Figure 2. Mutant p53 gain of function (GOF) in metabolism and invasion. (A). Mutant p53 proteins
promote invasion and migration by inhibiting p63 and p73 function, enhancing STAT3 (Signal Transducer
And Activator Of Transcription) signaling and vascular endothelial growth factor receptor (VEGFR)
expression. (B). Mutant p53 proteins promote glycolysis by upregulating glucose transporter GLUT1
translocation to the plasma membrane. In addition, mutant p53 proteins stimulate the mevalonate
pathway through a physical interaction with SREBPs (Sterol Regulatory Element Binding Transcription
Factors), and enhance lipogenesis by inhibiting AMP-activated protein kinase (AMPK) signaling.
5. Mutant p53 Between Tumor Development and Self-Renewal
According to the cancer stem cell hypothesis, tumors are initiated and sustained by a small fraction
of cells termed cancer stem cells (CSCs) or tumor-initiating cells, that have the ability to self-renew as
well as to differentiate into various lineages. It is quite commonly accepted that CSCs are responsible for
tumor chemoresistance and relapse, thus representing an important therapeutic target [92]. CSCs are
thought to originate from normal stem cells (SCs) that underwent oncogenic genetic modifications, or
from the dedifferentiation of progenitor or somatic cells that gain stem cell like characteristics and
became CSCs [93]. Wt p53 has been shown to promote differentiation and restrain proliferation of
stem cells. In addition, wt p53 acts as a barrier for the reprogramming of terminally differentiated cells
into stem cell-like cells. Given these roles of p53 in the control of differentiation/de-dedifferentiation
processes, p53 mutations could influence stem cell differentiation, participating in cancer development
by facilitating CSC maintenance [94,95].
p53 mutants have been shown to facilitate the formation of CSC either by promoting oncogenic
transformation of adult stem cells, or the dedifferentiation of somatic cells. In particular, humanized
mouse models harboring mutant p53 show a higher number of mesenchymal and hematopoietic SCs,
compared to p53-null mice [63]. Interestingly, bone and soft-tissue sarcoma, whose incidence is very
high in Le-Fraumeni patients [96], has been suggested to arise from defective mesenchymal stem cells
(MSCs) [97,98]. Indeed, MSCs heterozygous for mutant p53 frequently undergo to p53 LOH that result
in an increase tumorigenic potential [99]. Likewise, mutant p53, by promoting human osteosarcoma
cells dedifferentiation, leads to increased proliferation, invasiveness, and resistance to apoptosis [100].
A further study shows that a Trp53R172H mutation promotes the initiation and the maintenance of
acute myeloid leukemia (AML), by enhancing the self-renewal property of hematopoietic stem and
progenitor cells (HSPC). Mechanistically, mutant p53 exerts this GOF activity by upregulating the
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expression of the Foxh1 (Forkhead Box H1) gene, which encodes a key transcription factor involved in
the regulation of stem cell-associated genes [101].
6. Role of Mutant p53 Gain of Function in Metabolism and Hypoxia
p53 mutations have also been associated to deregulation of cellular metabolism, independently
from the primary role that the wt p53 exerts. In breast cancer cells, p53 mutants stimulate the
mevalonate pathway. This pathway is responsible for the production of cholesterol that in turn
is required for membrane biogenesis and cell division. p53 mutants exert this function acting as
coactivators of SREBPs (Sterol Regulatory Element Binding Transcription Factors) proteins (SREBP-1
and SREBP-2), that are transcription factors promoting the expression of key mevalonate pathway
enzymes [102]. In particular, co-immunoprecipitation experiments show that mutant p53 interacts
with SREPBs proteins (Figure 2B). Furthermore, chromatin immunoprecipitation (ChIP) analysis
have identified mutant p53 binding in the proximity of SREBPs binding sites in the promoter of
SREBPs target genes. SREBPs are required for mutant p53 recruitment on these promoters. Indeed,
depletion or pharmacological inactivation of SREBPs partially abolishes mutants p53 recruitment on
the promoters of these genes. The stimulation of the mevalonate pathway by p53 mutants is necessary
to maintain the malignant state. Indeed, under 3D culture conditions, p53 mutated breast cancer cells
form highly disorganized and invasive structures, that were reverted toward acinus-like structures
following mutant p53 depletion. The supplementation of p53 mutated breast cancer cells in 3D culture
with mevalonate pathway intermediates impairs the phenotypic reversion caused by mutant p53
downregulation. Coherently, the pharmacologic inhibition of the mevalonate pathway recapitulates
the effects of knocking down mutant p53 [103–106]. Interestingly opposing mutant p53, wild type p53
represses the mevalonate pathway. In particular, the activation of wild type p53 inhibits SREBP-2
maturation, leading to the downregulation of its target genes. Wild type p53 affects SREBP-2 maturation
by activating the transcription of the cholesterol transporter gene ABCA1 (ATP Binding Cassette
Subfamily A Member 1), that has been reported to mediate the retrograde transport of cholesterol
from the plasma membrane to the endoplasmic reticulum (RE), suppressing SREBP-2 maturation.
In line with this, in a mouse model of liver cancer, the ablation of ABCA1, similarly to p53 loss,
promoted tumorigenesis and was associated with increased SREBP-2 maturation [107]. Furthermore,
under conditions of metabolic stress, mutant p53 increases lipid production and aerobic glycolysis
(i.e., the Warburg effect) by inhibiting AMP-activated protein kinase (AMPK) signaling. AMPK is
a cellular energy sensor that is activated in response to a decrease in ATP (adenosine triphosphate)
and a parallel increase in AMP (adenosine monophosphate) or ADP (adenosine diphosphate) levels.
After activation, AMPK increases ATP production by promoting catabolic pathways, and inhibiting
anabolic processes. AMPK is a serine/threonine protein kinase heterotrimer, composed of a catalytic
subunit (α), and two regulatory subunits (β and γ). In response to energy stress, AMPK activation
requires the AMP or ADP binding to the γ regulatory subunit. This binding leads to conformational
changes that allows the activating phosphorylation of the Thr172 residue in the AMPKα subunit
by the serine/threonine kinase LKB1 [108]. Mutant p53 inhibits AMPK activation by binding the
AMPKα subunit and blocking its Thr172 phosphorylation by LKB1 (Liver Kinase B1), or impairing
AMPKα-LKB1 interaction (Figure 2B) [109,110].
Hypoxia is a common characteristic of solid tumors. Tumor cells generally adapt to hypoxic
stress by activating numerous intracellular signaling pathways that promote angiogenesis, and the
acquisition of a more invasive and metastatic phenotype that allows tumor cells to survive or escape
from the hypoxic environment [111,112]. Mutant p53 has been shown to promote cancer cell adaptation
to hypoxia. First, mutant p53 stimulates neo-angiogenesis in tumors by increasing the production
of VEGF (Vascular Endothelial Growth Factor) in bone marrow stromal cells [113], or upregulating
ID4 (Inhibitor Of DNA Binding 4), that in turn increases the secretion of pro-angiogenic cytokines
such as IL-8 [114]. In addition, mutant p53 induces VEGFR2 (vascular endothelial growth factor
receptor 2) expression, leading to increased cellular growth. Interestingly, mutant p53 cooperates
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with the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex to remodel the chromatin architecture
at the VEGFR2 promoter (Figure 2A) [115]. Interestingly under hypoxic conditions, p53 mutant
cooperates with HIF-1 (hypoxia-inducible factor 1), the master transcriptional regulator of the cellular
response to oxygen deprivation, to selectively regulate the expression of specific HIF-1-responsive
genes. In particular, p53 mutants interact with HIF-1, forming a complex promoting the transcription
of extracellular matrix (ECM) genes such as type VIIa1 collagen (COL7A1) and laminin-γ2 (LAMC2)
(Figure 3). Mechanistically, the selectivity of the p53 mutant/HIF-1 transcriptional complex on
this specific subset of genes involves chromatin remodeling mediated by the SWI/SNF complex.
This complex does not affect the recruitment of mutant p53/HIF-1 to the genomic regions of type VIIa1
collagen and laminin-γ2 ECM genes, but it is required for their hypoxia-dependent up-regulation.
The analysis of the chromatin architecture at the type VIIa1 collagen and laminin-γ2 promoter regions,
reveals the requirement of mutant p53 to maintain a more open and transcriptionally accessible status.
These data suggest that mutant p53 facilities the chromatin remodeling activity of SWI/SNF at the
genomic regions of these ECM genes, promoting their expression. The transcriptional activation of
these ECM genes by p53 mutant/HIF-1 complex is associated with the acquisition of an aggressive
phenotype both in vivo and in vitro. Indeed, while mutant p53 depletion impairs hypoxia mediated
invasion and migration in non-small cell lung cancer (NSCLC), the ectopic expression of VIIa1
collagen and laminin-γ2 reverts this impairment. Similarly, in a cancer mouse model obtained by
hypoxic preconditioned non-small cell lung cancer xenotransplantation into immunocompromised
mice, the depletion of mutant p53 was associated with reduced tumor growth that was reverted by
the overexpression of laminin-γ2 or type VIIa1 collagen. Coherently, in human NSCLC patients,
the expression of these ECM genes is correlated with HIF-1 activation exclusively in patients carrying
p53 mutations, and is associated with a worse prognosis [116,117].
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Figure 3. Mutant p53 GOF and hypoxia. In response to hypoxia, p53 mutant forms a complex
with hypoxia-inducible factor 1 (HIF-1) that physically binds the SWI/SNF chromatin remodeling
complex, promoting expression of extracellular matrix (ECM) components such as Laminin-γ2 and
type VIIa1 collagen (COL7A1). On the other hand, increased ECM stiffening induces HDAC6/ Heat
shock protein 90 (Hsp90)-dependent stabilization of mutant p53 from ubiquitin-mediated proteolysis,
through a mechanism that involves RhoA geranylgeranylation downstream of the mevalonate pathway.
The purple and green arrows indicate promotion and inhibition, respectively.
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A further study shows that the increase in ECM stiffness induces mutant p53 stabilization that
is a prerequisite for the manifestation of their gain-of-function (GOF) properties. In cancer cells
mutant p53 proteins are stabilized by the interaction with Heat shock protein 90 (Hsp90) chaperones.
This binding results in the formation of complexes protecting mutant p53 from E3 ligase MDM2
ubiquitination. The increase in matrix stiffness is a common feature in solid tumors, and in this context
the small GTPase RhoA (Ras Homolog Family Member A) plays an important role, by transducing the
mechanical stimulus from the extracellular environment. RhoA-mediated mechanotransduction has
been shown to promote the accumulation of mutant p53. In particular, RhoA signaling activation has
been shown to promote the binding of Hsp90 to mutant p53, resulting in its stabilization. The RhoA
mediated mechanosignaling in turn requires the mevalonate pathway. Indeed, in addition to cholesterol
biosynthesis, this pathway also provides geranylgeranyl pyrophosphate (GGPP) that is required for
cellular membrane anchoring, and activation of RhoA (Figure 3) [118]. Thus, p53 mutants promote the
mevalonate pathway [103], whose activation in turn induces the accumulation of mutant p53 protein
in cancer cells.
7. Tumor Dependency to Mutant p53
Within tumors, cancer cells are constantly exposed to several stresses such as hypoxia, starvation,
and exposure to anticancer drugs. To survive, cancer cells can develop adaptation to stress conditions,
such as the eventual mutation of p53 at a very late stage. Indeed, as discussed in the above sections,
p53 mutations cause loss of tumor suppressive functions as well as gain of new pro-tumorigenic activity,
that allows cancer cells to adapt to the challenging conditions typically present in the tumor. Thus, it is
not surprising that tumor cells can develop a dependency to mutant p53 expression. The constitutive
depletion of mutant p53 results in a decrease in tumor growth, invasion, and angiogenesis in nude
mice [119]. In addition, mutant p53 depletion in breast cancer cells in 3D culture lead to a phenotypic
reversion from a disordered and invasive morphology to more physiological, differentiated structures.
A further study using a conditional mutant p53 mouse model expressing an inactivable R248Q
mutation, showed that mutant p53 ablation decreases tumor growth extending animal survival [120].
These evidences have clearly demonstrated that most of the cancer cells expressing mutant p53 require
its expression to survive, or at least maintain their tumorigenic capabilities. In a recent in vivo study of
a mouse model of colorectal cancer (CRC), mutant p53 R248Q was shown to interact with phospho-
Signal Transducer And Activator Of Transcription 3 (p-STAT3), to block its interaction with the tyrosine
phosphatase SHP2 (Protein Tyrosine Phosphatase Non-Receptor Type 11). Consequently, the binding
of mutant p53 R248Q to pSTAT3 prevents its dephosphorylation, leading to the hyperactivation of
STAT3 signaling pathway that in turn drives cancer progression, by inducing the expression of target
genes such as CCND1 (Cyclin D1), CCNB1 (Cyclin B1), and MYC (MYC Proto-Oncogene,) (Figure 2A).
The genetic ablation of mutant p53 R248Q reduces tumor growth and invasion [121]. All together
these data indicate that tumors display a dependency to mutant p53 expression to sustain their growth,
posing mutant p53 as an attractive target for cancer therapy. Identification of the basis of control of
mutant p53 expression and protein stability therefore represents a priority in the field, to develop
strategies to target mutant p53 expressing tumors.
8. Targeting Mutant p53 for Therapy
To date, several strategies are being explored to target mutant p53 for cancer therapy. One approach
uses small molecular compounds to directly target mutant p53, in order to induce its degradation
or the restoration of its transcriptional tumor-suppressive activity. A second approach exploits
tumor addiction to mutant p53 GOF targeting pathways, induced by gain-of-function p53 mutants.
Another promising strategy aims to promote p53 function by targeting its antagonists such as the E3
ligase, Mdm2.
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8.1. Therapies to Restore Wild Type p53 Functions
As expected, re-expression of wild type p53 in p53-null or p53 mutant tumors is sufficient to
induce tumor regression [122,123]. Therefore, significant efforts have been focused to develop strategies
based on small molecules that could reactivate wild type p53 functions in tumor cells carrying mutant
p53 proteins. The main goal of these mutant p53 targeting compounds is to promote a conformational
change in mutant p53 folding, in order to restore the physiological transcriptional activity of p53 and
induce it anti-tumor activity. As one of the first developed compounds, PRIMA-1 can induce mutant
p53 proteins to refold into a wild type conformation, restoring wild type p53-like transcriptional activity,
and inducing the expression of PUMA, NOXA, and BAX target genes [124,125]. The methylated
analogue of PRIMA-1, PRIMA-1Met (APR-246), is more potent and less toxic [126]. At the chemical level,
PRIMA-1 is converted inside cells into the active form methylene quinuclidinone (MQ). The interaction
of this metabolite with cysteine residues of mutant p53 protein causes its proper refolding to wild
type p53 [127]. PRIMA-1 is a prototype compound for this activity; however, the specificity of its
effects is still being discussed, as part of its cytotoxic effect seems to be associated with alterations to
cellular antioxidant machinery. To date, PRIMA-1 is undergoing phase 3 clinical trials, and represents
a promising alternative therapeutic strategy for cancer patients.
8.2. Therapies to Induce Mutant p53 Degradation
Detection of p53 protein expression in tumor tissue is a read-out of p53 mutant status. In cancers,
mutant p53 is indeed much more stable than wild type p53, and positive staining is generally observed in
primary material as well as in cell lines. Mutant p53 stability has been ascribed to its interaction with the
Histone Deacetylase 6/ Heat Shock 90kD Protein 1 (HDAC6/Hsp90) chaperone complex that stabilizes
mutant p53, preventing its degradation mediated by MDM2 E3 ubiquitin ligase [128,129]. Therefore,
compounds able to disrupt this HDAC6/HSP90 complex are being developed in order to promote
mutant p53 degradation. These compounds, including both Hsp90 inhibitors (17-AAG and ganetespib)
and HDAC inhibitors (such as SAHA or vorinostat), are able to promote proteasome-dependent
degradation of mutant p53 [120,130]. Another class of compounds able to induce degradation of
mutant p53 proteins are statins. These compounds preferentially induce degradation of conformational
p53 mutants. Mechanistically, statins inhibit the mevalonate-5-phosphate pathway and induce E3
Ubiquitin-Protein Ligase CHIP -mediated degradation of mutant p53, by impairing the interaction of
mutant p53 with DNAJA1 (DnaJ Heat Shock Protein Family Member A1), an Hsp40 isoform, similarly to
Hsp90s involved in mutant p53 protection [131]. As mentioned above, statins also degrade mutant p53
proteins by interfering with the mevalonate-geranylgeranyl-pyrophosphate-RhoA mechanosignaling
pathway, which controls Hsp90-dependent p53 mutant stabilization [118]. Overall, bi-directional
interactions between mutant p53 and the mevalonic pathway could be a promising therapeutic target.
8.3. Targeting Mutant p53 GOF
The novel oncogenic functions acquired by mutant p53 proteins contribute to tumor development
and progression. For example, p53 mutants can activate cell migratory pathways able to stimulate
migration, invasion, and metastasis. Therefore, the inhibition of the downstream pathways triggered
by mutant p53 GOF represents an alternative strategy for effective treatment of p53-mutant cancers.
For example, in a mouse model of pancreatic ductal adenocarcinoma (PDAC) mutant p53 promoted
invasion and metastasis, by enhancing platelet-derived growth factor receptor beta (PDGFRβ) signaling.
Interestingly, treatment of p53-mutant pancreatic cancers with imatinib, an inhibitor of PDGFRβ
signaling, is effectively able to impair cell invasion and metastasis [91]. Another pathway that could be
targeted for the treatment of p53-mutant cancers is the RhoA/ROCK pathway. Mutant p53 R172H has
been shown to increased Ras Homolog Family Member A /Rho Associated Coiled-Coil Containing
Protein Kinase (RhoA/ROCK) signaling that in turn promotes glucose transporter GLUT1 (Glucose
Transporter Type 1) translocation to the plasma membrane (Figure 2B). This results in an increased
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glucose uptake that promotes glycolysis, and ultimately tumorigenesis. An in vivo experiment showed
that Dasatanib treatment inhibited the activity of RhoA and impaired the invasive potential of p53
R172H cells [132].
8.4. Targeting p53 in Wild Type p53 Tumours: MDM2 Inhibition
MDM2 is a E3 ubiquitin ligase that controls cellular levels of p53. In unstressed conditions,
MDM2 maintains low levels of p53 by mediating its proteasomal-dependent degradation. In response
to stress, both MDM2 and p53 undergo post-translational modifications that impair their interaction,
allowing p53 to accumulate and exert its tumor-suppressive functions. Interestingly, the mdm2 gene is
amplified in more than 17% of tumors resulting in p53 inactivation. Thus, a current therapeutic strategy
is based on the use of drugs able to block MDM2, which include MDM2 antagonists (such as Nutlin-3)
and inhibitors of MDM2-p53 interaction (MI-219 and MI-319), in p53 wild type tumors [133,134].
9. Conclusions
Mutations in p53 have far reaching consequences for the biology of the cancer cells, especially
when associated with the expression of neomorphic p53 proteins. GOF p53 mutants can help malignant
cells to survive and adapt to stresses, such as hypoxia, nutrient deprivation, etc. Thus, tumor cells
obtain selective advantages by maintaining the mutant forms of the protein, beyond the loss of wt p53
function. The signaling triggered by GOF proteins might underlie the cancers addiction to mutant p53,
and this opens potential therapeutic strategies to target aggressive late stage cancers. While a better
understanding of GOF mechanisms is still needed [129,135], a pragmatic effort should also be invested
in, developing approaches to promote degradation of mutant p53 to treat lethal cancers.
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